The copper(I) complex [CuI(9-AQH)2]⋅NO3[\mathrm{Cu}^{\mathrm{I}}(9\text{-AQH})_{2}]\cdot\mathrm{NO}_{3} (9-AQH = anthracene-9-quinolylhydrazone), reported in 2021 as the first Cu(I) complex of an anthrahydrazone ligand, shows broad-spectrum in vitro anticancer activity through mitochondria-mediated apoptosis together with concurrent autophagy, yet its cellular mechanism of action remains undetermined. In solution the complex is stable against oxidation but catalyzes Fenton-like hydroxyl-radical generation from hydrogen peroxide; in treated tumor cells, however, no Cu(II) electron-paramagnetic-resonance signal could be detected and the total intracellular reactive-oxygen-species level decreased — a mechanistic paradox the source study could not resolve. The source authors left open whether intracellular Cu(I)/Cu(II) redox cycling occurs and can be directly detected, whether Fenton-like chemistry contributes to cytotoxicity, and whether the induced autophagy is pro-death or pro-survival and how it relates to apoptosis — together with the related question of whether the inactive Co(II), Ni(II), and Zn(II) analogues are deactivated intracellularly by glutathione. None of these questions has been answered; the problem remains open.

Background

Platinum drugs remain the only metal-based anticancer agents in wide clinical use, and medicinal inorganic chemistry has long sought alternatives that exploit the redox chemistry of endogenous metals. Copper is attractive because tumor cells accumulate it and because the Cu(II)/Cu(I) pair can undergo redox cycling: Cu(I) reacts with hydrogen peroxide (H2O2) in a Fenton-like reaction to generate hydroxyl radicals (•OH), highly reactive oxygen species (ROS) that damage DNA, proteins, and membranes. A persistent design problem is that Cu(II) complexes, while often potently cytotoxic, tend to be unselectively toxic, in part through Cu(II)-driven ROS generation; low-valent Cu(I) complexes have been proposed as a way to keep the Cu(II)/Cu(I) couple available while moderating the indiscriminate oxidant burden.

The anthracyclines (e.g., doxorubicin) are frontline antitumor drugs whose dose-limiting cardiotoxicity is attributed to their anthraquinone core; replacing the quinone with a hydrazone linkage, as in the clinical antitumor drug bisantrene, reduces cardiac toxicity. Hydrazones are azomethine (C=N–N) compounds formed from an aldehyde or ketone and a hydrazide or hydrazine; anthrahydrazones carry the anthracene polycycle. The group of Liang, Liu, and Chen had previously shown that Cu(II) complexes of new anthrahydrazone ligands are active in vitro and in vivo but highly cytotoxic (Liu et al., J. Inorg. Biochem. 2020, DOI 10.1016/j.jinorgbio.2020.111208). In 2021 they reported the first Cu(I) complex of an anthrahydrazone: the ligand 9-AQH (anthracene-9-quinolylhydrazone, joining the anthrahydrazone pharmacophore to the quinoline anticancer pharmacophore) affords [CuI(9-AQH)2]⋅NO3[\mathrm{Cu}^{\mathrm{I}}(9\text{-AQH})_{2}]\cdot\mathrm{NO}_{3} (complex 3), formed reproducibly by in situ reduction when the Cu(II) salt reacts with the ligand (Liu et al., J. Inorg. Biochem. 2021).

Of the four 9-AQH complexes reported — [CoII(9-AQH)(NO3)2(H2O)][\mathrm{Co}^{\mathrm{II}}(9\text{-AQH})(\mathrm{NO}_{3})_{2}(\mathrm{H}_{2}\mathrm{O})] (1), [NiII(9-AQH)2(H2O)2]⋅2NO3[\mathrm{Ni}^{\mathrm{II}}(9\text{-AQH})_{2}(\mathrm{H}_{2}\mathrm{O})_{2}]\cdot 2\mathrm{NO}_{3} (2), complex 3, and [ZnII(9-AQH)2(NO3)]⋅NO3[\mathrm{Zn}^{\mathrm{II}}(9\text{-AQH})_{2}(\mathrm{NO}_{3})]\cdot\mathrm{NO}_{3} (4) — only the Cu(I) complex 3 showed significant broad-spectrum activity (half-maximal inhibitory concentration, IC50_{50}, of about 7.5 μM against MGC-803 gastric cancer cells), indicating that the Cu(I) center is decisive. Its solution chemistry is well characterized: high-resolution mass spectrometry, 1^{1}H NMR, and EPR (electron paramagnetic resonance; Cu(II), d9^{9}, is paramagnetic and EPR-detectable, whereas Cu(I), d10^{10}, is diamagnetic and EPR-silent) showed no oxidation of Cu(I) to Cu(II) over 24 h in DMSO-containing media, with the cation [CuI(9-AQH)2]+[\mathrm{Cu}^{\mathrm{I}}(9\text{-AQH})_{2}]^{+} as the dominant species; spin-trapping EPR with DMPO (5,5-dimethyl-1-pyrroline N-oxide, a spin trap that converts short-lived radicals into EPR-detectable adducts) demonstrated that complex 3 catalyzes hydroxyl-radical generation from H2O2; and DPPH and ABTS assays (two standard colorimetric radical-scavenging assays) showed strong intrinsic radical-scavenging (antioxidant) activity.

Inside cells the picture inverts in an unexplained way. In MGC-803 cells treated with complex 3, standard EPR detected no Cu(II) signal — neither in whole cells nor in isolated nuclear and mitochondrial fractions, even after oxidative H2O2/HNO3 digestion — and the total intracellular ROS level decreased rather than increased. Nevertheless, the complex killed cells through mitochondria-mediated apoptosis (loss of mitochondrial membrane potential in JC-1 assays (JC-1 being a voltage-sensitive mitochondrial dye); activation of caspase-9 and caspase-3) without substantial cell-cycle arrest, inhibited topoisomerase I (a DNA-processing enzyme and a classical anticancer drug target) more strongly after preincubation, and, unexpectedly, induced autophagy. Autophagy ('self-eating') is the lysosome-dependent cellular degradation pathway; it can rescue cells under stress (pro-survival) or, when excessive, contribute to cell death (pro-death), and its functional role is compound-specific, established only by perturbation experiments (e.g., knockdown of autophagy-related (ATG) genes or lysosomal inhibitors). The source authors could not determine whether the observed autophagy was a concurrent death mechanism, a pro-survival rescue attempt, or an independent stress response.

Adjacent work explains why the intracellular questions are hard and confirms they are unresolved. The cytosol contains millimolar glutathione (GSH, the tripeptide γ-Glu-Cys-Gly and the cell's dominant small-molecule reductant and thiol buffer) together with metallothioneins, which reduce Cu(II) and strip copper from ligands that bind it weakly; Santoro et al. (Angew. Chem. Int. Ed. 2020) showed that such cytosolic ligands can dissociate or inactivate Cu(I)/Cu(II) drug candidates. This is also the rationale for the source's hypothesis that the inactive Co(II), Ni(II), and Zn(II) 9-AQH analogues — whose coordination spheres retain labile water/nitrate sites — are deactivated inside cells by coordination to GSH or proteins before reaching their targets. For the anticancer copper-phenanthroline system, Falcone et al. (Angew. Chem. Int. Ed. 2025) showed that speciation evolves in glutathione-rich media and that a minor ternary Cu(I)–GSH–phenanthroline species, more populated at lysosomal pH, is the actual redox-active species generating hydroxyl radicals, with toxicity dependent on lysosomal acidification. That work demonstrates that compartment- and speciation-resolved intracellular answers are attainable with current methods — and that no comparable answer exists for the anthrahydrazone Cu(I) system.

Problem Statement

Determine the intracellular fate and cell-death mechanism of the copper(I) anthrahydrazone complex [CuI(9-AQH)2]⋅NO3[\mathrm{Cu}^{\mathrm{I}}(9\text{-AQH})_{2}]\cdot\mathrm{NO}_{3} (complex 3; 9-AQH = anthracene-9-quinolylhydrazone) in tumor cells, by resolving the mechanistic questions that Liu et al. (J. Inorg. Biochem. 218 (2021) 111390) left open, together with the related intracellular question raised for the inactive analogues:

  1. Intracellular redox cycling. Does complex 3 undergo Cu(I)/Cu(II) redox cycling inside cells? A satisfactory answer must either directly detect Cu(II) derived from complex 3 intracellularly (e.g., EPR on whole cells or subcellular fractions with adequate positive controls and quantified detection limits, X-ray absorption near-edge spectroscopy at the Cu K-edge, or oxidation-state-specific probes), or establish a quantitative upper bound on the intracellular Cu(II) fraction low enough to exclude a material contribution of Fenton-like hydroxyl-radical generation (Cu(I) + H2O2) to the observed cytotoxicity. The resolution must reconcile the three currently contradictory observations: solution-phase Fenton-like •OH catalysis, intracellular net ROS decrease, and mitochondria-mediated apoptosis.

  2. Autophagy function and its link to apoptosis. Is the autophagy induced by complex 3 pro-death, pro-survival, or an independent stress response? This must be established functionally — by pharmacological autophagy inhibition or genetic knockdown or knockout of autophagy-related (ATG) genes — with measured consequences for apoptotic markers (caspase-9/caspase-3 activation, Annexin-V staining, an apoptotic-cell marker) and cell viability, thereby determining how autophagy relates to the mitochondrial apoptotic pathway.

  3. Intracellular deactivation of the analogues. Are the inactive Co(II), Ni(II), and Zn(II) 9-AQH complexes (complexes 1, 2, 4) deactivated inside cells by coordination to glutathione or proteins, as hypothesized, or is their inactivity due to another cause (uptake, speciation, intrinsic reactivity)?

These three questions jointly concern the cellular mechanism of the first Cu(I) anthrahydrazone anticancer family: components 1 and 2 address the intracellular oxidation-state fate of complex 3 and the assignment of its death pathway, including the role of autophagy within it, and component 3 addresses the cause of the analogues' inactivity. Resolve each component by an argued determination grounded in the cited data and the surrounding literature, and, where the existing evidence leaves a component undecided, by a concrete experimental design with quantitative decision criteria by which that component would be established; these determinations and designs are the deliverable, and executing the experiments is not required.

References

  1. Rui-Xue Liu, Ru-Yi Luo, Meng-Ting Tang, Yan-Cheng Liu, Zhen-Feng Chen, Hong Liang, 'The first copper(I) complex of anthrahydrazone with potential ROS scavenging activity showed significant in vitro anticancer activity by inducing apoptosis and autophagy', Journal of Inorganic Biochemistry 218 (2021) 111390, DOI 10.1016/j.jinorgbio.2021.111390, https://doi.org/10.1016/j.jinorgbio.2021.111390
  2. Rui-Xue Liu, Chen-Yu Wang, Ying-Shu Wu, Ru-Yi Luo, Xiao-Hong Jiang, Meng-Ting Tang, Yan-Cheng Liu, Zhen-Feng Chen, Hong Liang, 'The copper(II) complexes of new anthrahydrazone ligands: In vitro and in vivo antitumor activity and structure-activity relationship', Journal of Inorganic Biochemistry 212 (2020) 111208, DOI 10.1016/j.jinorgbio.2020.111208, https://doi.org/10.1016/j.jinorgbio.2020.111208
  3. Ruixue Liu, Jingbo Cui, Tongyan Ding, Yancheng Liu, Hong Liang, 'Research Progress on the Biological Activities of Metal Complexes Bearing Polycyclic Aromatic Hydrazones', Molecules 27 (2022) 8393, DOI 10.3390/molecules27238393, https://doi.org/10.3390/molecules27238393
  4. Narendra Kumar Singh, Paras Nath Yadav, 'Anticancer Potency of Copper(I) Complexes Against a Range Cancer Cell Lines: A Review', Journal of Institute of Science and Technology 26 (2021) 128-140, DOI 10.3126/jist.v26i1.37840, https://doi.org/10.3126/jist.v26i1.37840
  5. Bulat A. Faizullin, Irina R. Dayanova, Alexey V. Kurenkov, Aidar T. Gubaidullin, Alina F. Saifina, Irek R. Nizameev, Kirill V. Kholin, Mikhail N. Khrizanforov, Aisylu R. Sirazieva, Igor A. Litvinov, Alexandra D. Voloshina, Anna P. Lyubina, Guzel V. Sibgatullina, Dmitry V. Samigullin, Elvira I. Musina, Igor D. Strelnik, Andrey A. Karasik, Asiya R. Mustafina, 'ROS-producing nanomaterial engineered from Cu(I) complexes with P2N2-ligands for cancer cells treating', Discover Nano 18 (2023) 133, DOI 10.1186/s11671-023-03912-7, https://doi.org/10.1186/s11671-023-03912-7
  6. Chao Chen, Yilun Zheng, Hong Rao, Fan Huang, Chao Shen, Chunxin Lu, 'Copper(I) Complexes With Phenanthroline-Functionalized NHC Ligands Achieve Effective Anticancer Activity via Mitochondrial and Endoplasmic Reticulum Stress', Applied Organometallic Chemistry 39 (2025) e7756, DOI 10.1002/aoc.7756, https://doi.org/10.1002/aoc.7756
  7. Yuan-Yuan Fu, Shuyan Zeng, Zhenlin Wang, Huiting Huang, Xin Zhao, Min Li, 'Mechanisms of Copper-Induced Autophagy and Links with Human Diseases', Pharmaceuticals 18 (2025) 99, DOI 10.3390/ph18010099, https://doi.org/10.3390/ph18010099
  8. Rui-Xue Liu, Dong-Mei Li, Ru-Yi Luo, Xue-Bin Bi, Yue Huang, Sha-Sha Luo, Ying-Shu Wu, Tong-Yan Ding, Jia-Xiu Xie, Chang-Chun Wen, Yan-Cheng Liu, Tim Storr, Hong Liang, 'The First Multimodal Anticancer Manganese(II) Complex of an Asymmetric Anthrahydrazone Triggers Apoptosis, Autophagy and Ferroptosis', Journal of Medicinal Chemistry 69 (2026) 6835-6853, DOI 10.1021/acs.jmedchem.5c03122, https://doi.org/10.1021/acs.jmedchem.5c03122
  9. Chao Liu, Xue-bin Bi, Jia-yu Xu, Rui-xue Liu, Shu-feng Zhang, 'Cobalt(II) and zinc(II) anthrahydrazone complexes: synthesis, crystal structure, divergent anticancer and antibacterial activities', Transition Metal Chemistry 51 (2026) 35, DOI 10.1007/s11243-026-00724-3, https://doi.org/10.1007/s11243-026-00724-3
  10. Alice Santoro, Jenifer S. Calvo, Manuel David Peris-Díaz, Artur Krężel, Gabriele Meloni, Peter Faller, 'The Glutathione/Metallothionein System Challenges the Design of Efficient O2-Activating Copper Complexes', Angewandte Chemie International Edition 59 (2020) 7830-7835, DOI 10.1002/anie.201916316, https://doi.org/10.1002/anie.201916316
  11. Enrico Falcone, Vincenzo Vigna, Hemma Schueffl, Francesco Stellato, Bertrand Vileno, Merwan Bouraguba, Gloria Mazzone, Olivier Proux, Silvia Morante, Petra Heffeter, Emilia Sicilia, Peter Faller, 'When Metal Complexes Evolve, and a Minor Species is the Most Active: the Case of Bis(Phenanthroline)Copper in the Catalysis of Glutathione Oxidation and Hydroxyl Radical Generation', Angewandte Chemie International Edition 64 (2025) e202414652, DOI 10.1002/anie.202414652, https://doi.org/10.1002/anie.202414652
  12. Yong-Po Zhang, Qing He, Xin-Hui Zhou, Guang-Huan Liu, Ai-Qin Yue, Chun-Yan Gao, Jin-Zhong Zhao, Wei-Jun Du, Shi-Ping Yan, 'In situ reduction synthesis of quinoline-based copper(I) complexes: "Self-activating" chemical nuclease, antioxidation and anticancer activity', Journal of Molecular Structure 1292 (2023) 136090, DOI 10.1016/j.molstruc.2023.136090, https://doi.org/10.1016/j.molstruc.2023.136090